Encompass Wealth Advisors LLC Invests $100,000 in Pfizer Inc. (NYSE:PFE)


Share on StockTwits

Encompass Wealth Advisors LLC bought a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, Holdings Channel.com reports. The firm bought 2,717 shares of the biopharmaceutical company’s stock, valued at approximately $100,000.

Other large investors also recently added to or reduced their stakes in the company. Security Asset Management boosted its holdings in Pfizer by 125.6% in the fourth quarter. Security Asset Management now owns 28,838 shares of the biopharmaceutical company’s stock valued at $1,062,000 after acquiring an additional 16,056 shares in the last quarter. Sowell Financial Services LLC boosted its holdings in Pfizer by 5.1% in the fourth quarter. Sowell Financial Services LLC now owns 309,093 shares of the biopharmaceutical company’s stock valued at $11,378,000 after acquiring an additional 15,071 shares in the last quarter. Wellington Shields Capital Management LLC boosted its holdings in Pfizer by 7.6% in the fourth quarter. Wellington Shields Capital Management LLC now owns 104,766 shares of the biopharmaceutical company’s stock valued at $3,856,000 after acquiring an additional 7,405 shares in the last quarter. State of Wisconsin Investment Board boosted its holdings in Pfizer by 18.1% in the fourth quarter. State of Wisconsin Investment Board now owns 6,040,242 shares of the biopharmaceutical company’s stock valued at $222,341,000 after acquiring an additional 924,796 shares in the last quarter. Finally, Sound Income Strategies LLC boosted its holdings in Pfizer by 34.5% in the fourth quarter. Sound Income Strategies LLC now owns 119,776 shares of the biopharmaceutical company’s stock valued at $4,409,000 after acquiring an additional 30,750 shares in the last quarter. Institutional investors and hedge funds own 67.36% of the company’s stock.

Shares of NYSE:PFE opened at $35.91 on Thursday. Pfizer Inc. has a fifty-two week low of $31.61 and a fifty-two week high of $43.08. The business has a 50-day simple moving average of $35.06 and a two-hundred day simple moving average of $36.58. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.13 and a current ratio of 1.40. The firm has a market cap of $200.29 billion, a price-to-earnings ratio of 23.17, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The business had revenue of $11.68 billion during the quarter, compared to analysts’ expectations of $11.32 billion. During the same period last year, the firm posted $0.55 EPS. Pfizer’s quarterly revenue was up 11.8% compared to the same quarter last year. As a group, research analysts predict that Pfizer Inc. will post 2.89 earnings per share for the current year.

PFE has been the topic of several recent analyst reports. Morgan Stanley cut their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a report on Friday, January 29th. JPMorgan Chase & Co. set a $36.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, February 3rd. Royal Bank of Canada started coverage on Pfizer in a research report on Wednesday. They set a “sector perform” rating and a $42.00 price objective for the company. Berenberg Bank reissued a “neutral” rating and set a $38.00 price objective on shares of Pfizer in a research report on Tuesday, March 23rd. Finally, Mizuho lowered their price objective on Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a research report on Wednesday, February 3rd. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $38.47.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Recommended Story: High-Yield Dividend Stocks

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.